美国 · 财经报刊 · Barron's
Why Pepsi’s Taco Bell Deal Is About Much More Than Fountain Drinks
The Food and Drug Administration agrees to review a New Drug Application for Vyglxia, Biohaven’s experimental spinocerebellar ataxia treatment. The stock is poised to rally 30% or…
在 Barron's 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.barrons.com)
